Difference between revisions of "Idecabtagene vicleucel (Abecma)"
Jump to navigation
Jump to search
(Created page with "Anti-BCMA CAR T-cells. ==Preliminary data== ===Multiple myeloma=== # '''CRB-401:''' Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, M...") |
m |
||
| Line 7: | Line 7: | ||
[[Category:Chimeric antigen receptor T-cells]] | [[Category:Chimeric antigen receptor T-cells]] | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category:Investigational]] | + | [[Category:Investigational drugs]] |
Revision as of 15:17, 1 July 2019
Anti-BCMA CAR T-cells.
Preliminary data
Multiple myeloma
- CRB-401: Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-cell therapy bb2121 in relapsed or refractory multiple myeloma. N Engl J Med. 2019 May 2;380(18):1726-1737. link to original article PubMed